Apolipoprotein-B synthesis inhibitors

PCT No. PCT/EP95/04111 Sec. 371 Date Apr. 9, 1997 Sec. 102(e) Date Apr. 9, 1997 PCT Filed Oct. 19, 1995 PCT Pub. No. WO96/13499 PCT Pub. Date May 9, 1996The present invention provides novel compounds of formula the N-oxides, the stereochemically isomeric forms thereof, and the pharmaceutically accep...

Full description

Saved in:
Bibliographic Details
Main Authors HEERES; JAN, VAN DER EYCKEN; LUC ALFONS LEO, DE CHAFFOY DE COURCELLES; DIDIER ROBERT GUY GABRIEL, HENDRICKX; ROBERT JOZEF MARIA, BACKX; LEO JACOBUS JOZEF
Format Patent
LanguageEnglish
Published 27.07.1999
Edition6
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:PCT No. PCT/EP95/04111 Sec. 371 Date Apr. 9, 1997 Sec. 102(e) Date Apr. 9, 1997 PCT Filed Oct. 19, 1995 PCT Pub. No. WO96/13499 PCT Pub. Date May 9, 1996The present invention provides novel compounds of formula the N-oxides, the stereochemically isomeric forms thereof, and the pharmaceutically acceptable acid addition salts thereof, wherein A and B taken together form a bivalent radical of formula: -N=CH- (a), -CH=N- (b), -CH2-CH2- (c), -CH=CH- (d), -C(=O)-CH2- (e), -CH2-C(=O)- (f); R1 is hydrogen, C1-6alkyl, or halo; R2 is hydrogen or halo; R3 is hydrogen; C1-8alkyl; C3-6cycloalkyl or C1-8alkyl substituted with hydroxy, oxo, C3-6cycloalkyl or aryl. Het is five- or six-membered optionally substituted heterocyclic ring. The use as a medicine, especially as a lipid lowering agent is disclosed as well as pharmaceutical compositions and processes for preparing compounds and compositions.
Bibliography:Application Number: US19970817247